What is it?
Oral solution for the combination therapy to antihypertensive treatment in glaucoma patients based on Cognizin® citicoline (50 mg / ml).
Food for special medical purposes, based on citicoline 50 mg/ml, indicated for dietary treatment of glaucoma patients, pharmacologically stabilised and with progressive loss of the visual field.
Citicoline promotes the biosynthesis of phospholipids of the optic nerve membrane. This structural action improves the function of mechanisms essential for correct neurotransmission. Citicoline maintains neuronal function, inhibits apoptosis and stimulates acetylcholine and dopamine synthesis. These neurotransmitters are involved in the conduction of the visual stimulus, both at the retinal and post-retinal level (central nervous system).
Indicated for
Glaucoma is a progressive disease characterised by a gradual reduction of the visual field. This reduction is also found in patients pharmacologically treated with antihypertensive eye drops, compromising quality of life.
Numerous scientific evidence has demonstrated how the introduction of citicoline in an oral solution in the diet of individuals suffering from glaucoma, already pharmacologically stabilised and with the progressive reduction of the visual field, positively influences vision, slowing the progression of glaucomatous damage and loss of the visual field.
Mode of use
Take 10 ml a day, which corresponds to 500 mg of citicoline.
Composition
Water, fructose, citicoline (Cognizin® Citicoline), trisodium citrate, sodium hydroxide, potassium permanganate, riboflavin.
Cognizin® is a registered trademark of KYOWA HAKKO BIO CO., LTD.
